Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug fenebrutinib met the main goal in a late-stage trial in patients with primary progressive multiple...
Roche's multiple sclerosis drug fenebrutinib meets goal in late-stage trial
